Tags: biotechpatientpharmaPolicy & Regulationpolicy-regulation
| Profile | Contacts | Recent Articles on Subject | |
|---|---|---|---|
| 1 | John Pinching PharmaTimes Next-gen biopharma company. La Jolla, California | Amlenetug receives FDA Fast Track Designation - 12 days ago Amgen’s lung cancer treatment gets conditional approval - about 2 months ago Andrew Caldwell - 11 months ago | |
| 2 | Frank Vinluan MedCity News Medical innovation tracker. MedCity, USA | Axsome Aims for FDA Filing in Alzheimer’s Agitation Despite Mixed Bag of Phase 3 Data - about 2 months ago The Chase for Novel Oral GLP-1 Obesity Meds Adds a New Contender - about 2 months ago | |
| 3 | Allison DeAngelis STAT News Reporter at STAT. Formerly Insider, BBJ. | STAT+: Axsome to send Alzheimer’s disease drug to FDA, despite mixed Phase 3 results - about 2 months ago | |
| 4 | Michael Gibney Pharma Voice Teacher of English. Teacher of politics. Santiago, Chile | Two former Alexion leaders fight through layoffs and a tough market to maintain a rare disease biotech - 4 months ago Ex-Novartis exec sets out to create ‘Apple of AI’ - 11 months ago A new delivery method muscling its way into the RNA space - over 1 year ago | |
| 5 | Kennedy Ferruggia, Assistant Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey | ||
| 6 | Amy Baxter Pharma Voice Scientist, inventor, former pediatrician. Atlanta, Georgia | ||
| 7 | Ashley Gallagher, Associate Editor Pharmacy Times One of Cabra girls on GoggleboxIRL. Dublin City, Ireland | ||
| 8 | Lizzy Lawrence STAT News Medical devices reporter at STATnews. Loves news tips. | ||
| 9 | Natasha Lomas TechCrunch Journalist. Climber-in-training. Owns cats. Barcelona and London | ||
| 10 | Elaine Chen STAT News Reporter at STATnews. Formerly at Business Insider. Chicago, Illinois | STAT+: Can amylin drugs best Wegovy and Zepbound? Companies bet on next big obesity target - 6 months ago It’s happy hour (for now) for Alnylam - 7 months ago |